Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lapatinib - Novartis

Drug Profile

Lapatinib - Novartis

Alternative Names: 572016; Cipatinib; GSK-572016; GW 572016; GW-2016; GW-572016F; Lapatinib - GlaxoSmithKline; Lapatinib ditosilate; Lapatinib ditosylate; Tykerb; Tyverb

Latest Information Update: 11 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; National Taiwan University Hospital; Novartis; West German Study Group
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Brain metastases
  • Phase II/III Bladder cancer
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Discontinued Gastric cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 06 Jun 2022 GlaxoSmithKline completes a phase III ALTERNATIVE trial in Breast cancer (Late stage disease, First-line therapy, Combination therapy) in in Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, South Africa, South Korea, Spain, Taiwan, Turkey, Ukraine, United Kingdom and USA (PO) (NCT01160211) (EudraCT2010-019577-16)
  • 03 Jun 2022 Efficacy data from a phase III Neo Altto trial in Breast cancer presented at the 58th annual meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 03 Jun 2022 Efficacy data from the phase III ALTTO trial in Breast cancer (adjuvant therapy) presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top